Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Neurodegenerative diseases
- Human polyglutamine diseases (1)
- Human polyglutamine diseases (2)
- Generating a model for this human disease class
- Initial polyQ model of SCA3
- Drosophila recreates human polyQ disease
- Expanded polyQ protein forms nuclear inclusions
- Time course of effects of polyglutamine protein
- Model for pathogenesis of expanded polyQ protein
- Is there a problem with molecular chaperones?
- Upregulating Hsp70 effects disease phenotype
- ATPase activity of Hsp70 and suppression
- Disease protein is sensitive to chaperones level
- Hsp70 does not alter protein aggregation
- Chaperones modulate protein solubility
- Disease protein forms nuclear inclusions
- Pathogenic polyQ protein is toxic in the cytoplasm
- Why is the protein so toxic to neuron?
- Normal axonal transport
- Cytoplasmic polyQ protein slows transport
- Nuclear protein does not disrupt axonal transport
- MJDtr-Q65-NLS shows no axonal accumulations
- Chaperones are powerful modifiers of the disease
- Hsp70 is a potent modulator of neurodegeneration
- Chaperones activity may be critical to disease
- Observations about ataxin-3 protein
- SCA3 has special features
- Host protein context vs. polyQ domain toxicity
- Drosophila SCA3 transgenes
- SCA3 causes neurodegeneration in flies
- Is normal ataxin-3 toxic?
- Co-expressing SCA-Q27 with SCA-Q78
- Ataxin-3 mitigates polyQ neurodegeneration
- Ataxin-3 causes less protein accumulation
- Ataxin-3 facilitates proteasomal degradation
- What part of ataxin-3 is required for suppression?
- Which domains are important for supression?
- Mutating domains in the N-terminal
- Mutation hurts ability of ataxin-3 to suppress
- Dependence on protein ubiquitin-related activities
- Two opposing activities of pathogenic ataxin-3
- Does pathogenic protein retain protective activity?
- Pathogenic ataxin-3 has two opposing activities
- Observations about ataxin-3 protein (2)
- SCA3 is associated with longer repeat expansions
- Other types of modifiers
- Genetic screens for modifiers of ataxin-3 toxicity
- A subclass of triplet repeat disease
- Can the fly reveal insight into repeat instability?
- The longer the repeat, the earlier the onset
- Multi- and single-generation schemes
- Repeat is stable through 9 generations
- Adding transcription of the gene
- Transcription induces repeat instability
- Different degrees of instability in different insertions
- Instability in a single generation with transcription
- CBP modulates repeat instability in Drosophila?
- Heterozygous loss of CBP enhances instability
- Pharmacological treatment to clamp instability
- A feed-forward loop for repeat instability in PGD
- Conclusions
- Acknowledgements
Topics Covered
- The fly as a model for human disease
- Modelling human polyglutamine disease
- Molecular chaperones as modifiers of polyglutamine disease using the fly
- Importance and impact of disease protein function for effects of the toxic mutant protein
- Insights from the fly on the mutational basis of disease, in instability of the trinucleotide repeat expansion
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Bonini, N. (2018, May 31). Human neurodegenerative disease: insights from Drosophila genetics [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/XYSK2514.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Nancy Bonini has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Human neurodegenerative disease: insights from Drosophila genetics
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
Our approach is to use the simple and
manipulable model organism Drosophila
in order to approach the complex problem
of human neurodegenerative disease.
0:12
So these are the types of
diseases that I'm talking about.
Parkinson's disease,
Alzheimer's disease, other dementias, as
well as the polyglutamine repeat diseases,
of which Huntington's disease
is probably the best known.
So these diseases share the fact that they
have a similar type of general phenotype
which is late onset and progressive,
neurodegenerative disease.
They also are associated with
pathological inclusions.
Those can be in different
places of the cell, and
they're composed of different
proteins in the different diseases.
But the fact that they have these
commonalities suggest that there might
be some commonalities among
these different diseases.
For all of these situations, genes have
been associated with the diseases and
with the gene, the typical ideas
to model those in other systems so
one can learn about disease mechanisms.
And whereas mouse or cells in culture
had been the popular way to go,
we decided to try Drosophila, which
has pathways very conserved to humans.
And if we could generate a phenotype
in the flies that looks like the human
disease, we could then apply the powerful
genetics of the fly to the problem.
1:17
So this illustrates the class of diseased
gene that I'm going to be talking about
which are the human polyglutamine
repeat disease genes,
of which there about 9 in humans.
I'm going to focus on our studies using
the spinocerebellar ataxia type 3 protein,
the SCA-3 protein, ataxin-3 is also
known as Machado Joseph Disease,
although probably the best known of
these diseases is Huntington's disease.
So on the right illustrates the mutational
mechanism responsible for these disease
genes, so it shows the genes and in red
it highlights the polyglutamine repeat
that becomes expanded out in these disease
situations, so all of these proteins have
a normal polyglutamine repeat and
that becomes expanded for disease.
The longer the expansion, the earlier
the onset and more severe the disease.
So in addition to being interested in
how that protein confers a toxicity that
causes the disease on the left-hand side
shows some of the features of the disease,
including the regions that are most
affected in the different diseases.
So an interesting feature of these
diseases is that despite the fact that
the disease proteins tend to be widely
expressed, they cause disease in only
certain sub-regions of the brain and that
indicates that there may be some degree of
cell specificity that perhaps is conferred
by the normal host protein context.